Clinical trials
Phase 4 Glaucoma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 6 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
| Recruiting | 6 |
| Terminated | 6 |
| Unknown status | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Allergan | 10 |
| Alcon Research | 8 |
| Innovative Medical | 5 |
| Indiana University | 4 |
| Oregon Health and Science University | 2 |
| Stanford University | 2 |
| University of California, Los Angeles | 2 |
| University of Miami | 2 |
| University of Michigan | 2 |
| Wills Eye | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glaucoma | 64 |
| Ocular Hypertension | 20 |
| Glaucoma, Open-Angle | 13 |
| Cataract | 2 |
| Dry Eye Syndromes | 2 |
| Hyperemia | 2 |
| Low Tension Glaucoma | 2 |
| Blepharoptosis | 1 |
| Eye Diseases | 1 |
| Graves Disease | 1 |
Trials
Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.